TY - JOUR
T1 - Deletion of the olfactomedin 4 gene is associated with progression of human prostate cancer
AU - Li, Hongzhen
AU - Rodriguez-Canales, Jaime
AU - Liu, Wenli
AU - Zhu, Jianqiong
AU - Hanson, Jeffrey C.
AU - Pack, Svetlana
AU - Zhuang, Zhengping
AU - Emmert-Buck, Michael R.
AU - Rodgers, Griffin P.
N1 - Funding Information:
Supported by the Intramural Research Program, NIH/National Institute of Diabetes and Digestive and Kidney Diseases .
PY - 2013/10
Y1 - 2013/10
N2 - The olfactomedin 4 (OLFM4) gene is located on chromosome 13q14.3, which frequently is deleted in human prostate cancer. However, direct genetic evidence of OLFM4 gene alteration in human prostate cancer has not yet been obtained. In this study, we investigated the genetics, protein expression, and functions of the OLFM4 gene in human prostate cancer. We found overall 25% deletions within the OLFM4 gene in cancerous epithelial cells compared with adjacent normal epithelial cells that were microdissected from 31 prostate cancer specimens using laser-capture microdissection and genomic DNA sequencing. We found 28% to 45% hemizygous and 15% to 57% homozygous deletions of the OLFM4 gene via fluorescence in situ hybridization analysis from 44 different prostate cancer patient samples. Moreover, homozygous deletion of the OLFM4 gene significantly correlated with advanced prostate cancer. By using immunohistochemical analysis of 162 prostate cancer tissue array samples representing a range of Gleason scores, we found that OLFM4 protein expression correlated inversely with advanced prostate cancer, consistent with the genetic results. We also showed that a truncated mutant of OLFM4 that lacks the olfactomedin domain eliminated suppression of PC-3 prostate cancer cell growth. Together, our findings indicate that OLFM4 is a novel candidate tumor-suppressor gene for chromosome 13q and may shed new light on strategies that could be used for the diagnosis, prognosis, and treatment of prostate cancer patients.
AB - The olfactomedin 4 (OLFM4) gene is located on chromosome 13q14.3, which frequently is deleted in human prostate cancer. However, direct genetic evidence of OLFM4 gene alteration in human prostate cancer has not yet been obtained. In this study, we investigated the genetics, protein expression, and functions of the OLFM4 gene in human prostate cancer. We found overall 25% deletions within the OLFM4 gene in cancerous epithelial cells compared with adjacent normal epithelial cells that were microdissected from 31 prostate cancer specimens using laser-capture microdissection and genomic DNA sequencing. We found 28% to 45% hemizygous and 15% to 57% homozygous deletions of the OLFM4 gene via fluorescence in situ hybridization analysis from 44 different prostate cancer patient samples. Moreover, homozygous deletion of the OLFM4 gene significantly correlated with advanced prostate cancer. By using immunohistochemical analysis of 162 prostate cancer tissue array samples representing a range of Gleason scores, we found that OLFM4 protein expression correlated inversely with advanced prostate cancer, consistent with the genetic results. We also showed that a truncated mutant of OLFM4 that lacks the olfactomedin domain eliminated suppression of PC-3 prostate cancer cell growth. Together, our findings indicate that OLFM4 is a novel candidate tumor-suppressor gene for chromosome 13q and may shed new light on strategies that could be used for the diagnosis, prognosis, and treatment of prostate cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=84884537387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884537387&partnerID=8YFLogxK
U2 - 10.1016/j.ajpath.2013.06.028
DO - 10.1016/j.ajpath.2013.06.028
M3 - Article
C2 - 24070418
AN - SCOPUS:84884537387
SN - 0002-9440
VL - 183
SP - 1329
EP - 1338
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 4
ER -